Business
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
About this update from Regenxbio Inc.
ROCKVILLE, Md. , Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Chardan's 9th Annual Genetic Medicines Conference Panel "Battleground States for Muscular Dystrophies": Tuesday, October 21 at 2:00 p.m. ET Panel "CNS GT – Lessons from Mature Programs & the Field's Next Frontiers": Tuesday, October 21 at 2:45 p.m. ET Location: New York, NY Guggenheim Securities 2nd Annual Healthcare Innovation Conference Fireside Chat: Monday, November 10, 2025 at 9:00 a.m. ET Location: Boston, MA Stifel 2025 Healthcare Conference Fireside Chat: Tuesday, November 11, 2025 at 1:20 p.m. ET Location: New York, NY Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com . Archived replays of the webcasts will be available for approximately 30 days following the events. ABOUT REGENXBIO Inc. REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM . Contacts: Dana Cormack Corporate Communications [email protected] Investors: George E. MacDougall Investor Relations [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302584430.html SOURCE REGENXBIO Inc.